A renaissance for cardio-metabolic surgery: Better outcomes and lower costs?

International Journal of Clinical Practice

Volumn 65, Issue 7, 2011, Pages 728-732

  Wierzbicki, A S ^a   Hubbard, J G H ^a   Botha, A J ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DARUSENTAN; LCZ 696; LIRAGLUTIDE; MIPOMERSEN; OMAPATRILAT; SAMAPATRILAT; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; VALSARTAN;

ANGIONEUROTIC EDEMA; APHERESIS; DISEASE SEVERITY; ENDOCRINE SURGERY; FAMILIAL HYPERCHOLESTEROLEMIA; HEALTH CARE COST; HEART SURGERY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERPARATHYROIDISM; HYPERTENSION; LAPAROSCOPIC SURGERY; LIFESTYLE MODIFICATION; MINIMALLY INVASIVE SURGERY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; STOMACH BYPASS; SURGICAL APPROACH; TREATMENT OUTCOME;

BARIATRIC SURGERY; BILIOPANCREATIC DIVERSION; CATHETER ABLATION; DENERVATION; DRUG RESISTANCE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; IMPLANTABLE NEUROSTIMULATORS; JEJUNOILEAL BYPASS; LAPAROSCOPY; OBESITY, MORBID; PRESSORECEPTORS; TREATMENT OUTCOME;

EID: 79959286463     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02696.x     Document Type: Review

References (53)

1. Lang BH,. Minimally invasive thyroid and parathyroid operations: surgical techniques and pearls. Adv Surg 2010; 44: 185-98.
2. Udelsman R, Lin Z, Donovan P,. The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann Surg 2011; 253: 585-91.
3. Chien D, Jacene H,. Imaging of parathyroid glands. Otolaryngol Clin North Am 2010; 43: 399-415.
4. Sackett WR, Barraclough B, Reeve TS, Delbridge LW,. Worldwide trends in the surgical treatment of primary hyperparathyroidism in the era of minimally invasive parathyroidectomy. Arch Surg 2002; 137: 1055-9. (Pubitemid 35006369)
5. Harrington PE, Fotsch C,. Calcium sensing receptor activators: calcimimetics. Curr Med Chem 2007; 14: 3027-34. (Pubitemid 350226971)
6. The Information Centre for Health and Social Care. Health Survey for England 2009: Trend Tables. London, UK: The NHS Information Centre for health and social care, 2011. Report No.: HSE 09 Trend tables.
7. Finucane MM, Stevens GA, Cowan MJ, et al., National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011; 377: 557-67.
8. National Collaborating Centre for Primary Care. Obesity: Guidance on the Prevention, Identification, Assessment and Management of Overweight and Obesity in Adults and Children. London, UK: National Institute for Health and Clinical Excellence, 2006 December Report No.: CG 43.
9. Wierzbicki AS,. Primary and secondary prevention in obesity. Int J Clin Pract 2007; 61: 1431-4. (Pubitemid 47228619)
10. Dansinger ML, Tatsioni A, Wong JB, Chung M, Balk EM,. Meta-analysis: the effect of dietary counseling for weight loss. Ann Intern Med 2007; 147: 41-50. (Pubitemid 351664633)
11. Rucker D, Padwal R, Li SK, Curioni C, Lau DC,. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194-9. (Pubitemid 350273303)
12. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L,. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-61. (Pubitemid 38196725)
13. Pratley RE, Nauck M, Bailey T, et al., Liraglutide vs. sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375: 1447-56.
14. Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR,. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord 2010; 10: 20.
15. Sjostrom L, Lindroos AK, Peltonen M, et al., Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683-93. (Pubitemid 39665322)
16. Sjostrom L, Narbro K, Sjostrom CD, et al., Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-52. (Pubitemid 47295641)
17. Podnos YD, Jimenez JC, Wilson SE, Stevens CM, Nguyen NT,. Complications after laparoscopic gastric bypass: a review of 3464 cases. Arch Surg 2003; 138: 957-61. (Pubitemid 37099869)
18. Thaler JP, Cummings DE,. Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology 2009; 150: 2518-25.
19. Vincent RP, le Roux CW,. New agents in development for the management of obesity. Int J Clin Pract 2007; 61: 2103-12. (Pubitemid 350077402)
20. Shikora SA, Bergenstal R, Bessler M, et al., Implantable gastric stimulation for the treatment of clinically severe obesity: results of the SHAPE trial. Surg Obes Relat Dis 2009; 5: 31-7.
21. Nass R, Pezzoli SS, Oliveri MC, et al., Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008; 149: 601-11.
22. Shearman LP, Wang SP, Helmling S, et al., Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice. Endocrinology 2006; 147: 1517-26. (Pubitemid 43244387)
23. Calhoun DA, Jones D, Textor S, et al., Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403-19.
24. Coats AJ,. Omapatrilat-the story of Overture and Octave. Int J Cardiol 2002; 86: 1-4.
25. Weber MA, Black H, Bakris G, et al., A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1423-31.
26. Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP,. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010; 375: 1255-66.
27. Novartis Pharmaceuticals. The efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality of patients with chronic heart failure (PARADIGM-HF). ClinicalTrials.gov. 9-12-2010. 11-1-2011.
28. Liu SY, Ng EK, Lee PS, et al., Radiofrequency ablation for benign aldosterone-producing adenoma: a scarless technique to an old disease. Ann Surg 2010; 252: 1058-64.
29. Johnson SP, Bagrosky BM, Mitchell EL, McIntyre RC Jr, Grant NG,. CT-guided radiofrequency ablation of an aldosterone-secreting primary adrenal tumor in a surgically unfit patient. J Vasc Interv Radiol 2008; 19: 1115-7.
30. Cannon B,. The effects of progressive sympathectomy on blood pressure. Am J Physiol 1931; 97: 592-6.
31. Smithwick RH, Thompson JE,. Splanchnicectomy for essential hypertension; results in 1,266 cases. JAMA 1953; 152: 1501-4.
32. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M,. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-9.
33. Doumas M, Douma S,. Renal sympathetic denervation: the jury is still out. Lancet 2010; 376: 1878-80.
34. Scheffers IJ, Kroon AA, Schmidli J, et al., Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010; 56: 1254-8.
35. Krum H, Schlaich M, Sobotka P, Scheffers I, Kroon AA, de Leeuw PW,. Novel procedure- and device-based strategies in the management of systemic hypertension. Eur Heart J 2011; 32: 537-44.
36. Thompson GR,. Recommendations for the use of LDL apheresis. Atherosclerosis 2008; 198: 247-55.
37. Kakaei F, Nikeghbalian S, Kazemi K, et al., Liver transplantation for homozygous familial hypercholesterolemia: two case reports. Transplant Proc 2009; 41: 2939-41.
38. Starzl TE, Chase HP, Ahrens EH Jr, et al., Portacaval shunt in patients with familial hypercholesterolemia. Ann Surg 1983; 198: 273-83. (Pubitemid 13050821)
39. Bilheimer DW,. Portacaval shunt surgery and liver transplantation in the treatment of homozygous familial hypercholesterolemia. Prog Clin Biol Res 1988; 255: 295-304.
40. Buchwald H, Varco RL, Matts JP, et al., Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323: 946-55. (Pubitemid 20332334)
41. Buchwald H, Williams SE, Matts JP, Nguyen PA, Boen JR,. Overall mortality in the program on the surgical control of the hyperlipidemias. J Am Coll Surg 2002; 195: 327-31. (Pubitemid 35006286)
42. Buchwald H, Rudser KD, Williams SE, Michalek VN, Vagasky J, Connett JE,. Overall mortality, incremental life expectancy, and cause of death at 25 years in the program on the surgical control of the hyperlipidemias. Ann Surg 2010; 251: 1034-40.
43. Buchwald H, Schone JL,. Gastric obesity surgery combined with partial ileal bypass for hypercholesterolemia. Obes Surg 1997; 7: 313-6. (Pubitemid 27423448)
44. DePaula AL, Macedo AL, Rassi N, et al., Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35. Surg Endosc 2008; 22: 706-16. (Pubitemid 351341683)
45. Wierzbicki AS, Hardman T, Prince WT,. Future challenges for microsomal transport protein inhibitors. Curr Vasc Pharmacol 2009; 7: 277-86.
46. Raal FJ, Santos RD, Blom DJ, et al., Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 998-1006.
47. Viljoen A, Wierzbicki AS,. Diagnosis and treatment of lipoprotein lipase deficiency. Expert Rev Cardiovasc Ther 2011. In press.
48. Wierzbicki AS, Reynolds TM,. Familial hyperchylomicronaemia. Lancet 1996; 348: 1524-5.
49. Wierzbicki AS, Reynolds TM, Crook MA,. Usefulness of Orlistat in the treatment of severe hypertriglyceridemia. Am J Cardiol 2002; 89: 229-31. (Pubitemid 34132918)
50. Gasbarrini G, Mingrone G, Greco AV, Castagneto M,. An 18-year-old woman with familial chylomicronaemia who would not stick to a diet. Lancet 1996; 348: 794. (Pubitemid 26308485)
51. Castagneto M, De GA, Mingrone G, et al., A surgical option for familial chylomicronemia associated with insulin-resistant diabetes mellitus. Obes Surg 1998; 8: 191-8. (Pubitemid 28279264)
52. Gaudet D, de WJ, Tremblay K, et al., Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler Suppl 2010; 11: 55-60.
53. Roos JC, Hyry HI, Cox TM,. Orphan drug pricing may warrant a competition law investigation. BMJ 2010; 341: c6471.